GlaxoSmithKline (GSK) has released an update.
Top executives at GSK plc, including CEO Emma Walmsley, have acquired additional ordinary shares through the reinvestment of dividends paid on April 11, 2024. The shares were purchased on the London Stock Exchange at a price of £16.1128 each, with transaction details made public in an initial notification. This strategic move by GSK’s leadership signifies their ongoing commitment to the company’s future.
For further insights into GSK stock, check out TipRanks’ Stock Analysis page.
